Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.

@article{Tomkinson2010InhaledVS,
  title={Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.},
  author={Alexandra Tomkinson and Joel Tepper and Margaret Morton and Alistair Bowden and Laurie A Stevens and Paul Harris and Dennis Lindell and Nicholas Fitch and Robert H. Gundel and Elise Burmeister Getz},
  journal={Allergy},
  year={2010},
  volume={65 1},
  pages={69-77}
}
BACKGROUND Pitrakinra is a recombinant protein derived from human interleukin-4 (IL-4) that binds to IL-4Ralpha and acts as a competitive antagonist of IL-4 and IL-13. The studies reported here compare the dose-ranging effects of pitrakinra on allergen-induced airway hyperresponsiveness (AHR) and airway eosinophilia when administered subcutaneously (s.c.) or by inhalation to the Ascaris suum-sensitive cynomolgus monkey for the purpose of elucidating the primary site of pitrakinra's anti… CONTINUE READING
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com